Esperion Agrees To Be Acquired By ARCHIMED In Deal Worth Upto $1.1 Bln, Stock Up
1/5 14:45
(RTTNews) - Esperion Therapeutics (ESPR), a biopharmaceutical company, on Friday announced that it has agreed to be acquired by funds managed by healthcare investment firm ARCHIMED in a deal valued at up to $1.1 billion....